AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2010637 — intervention group
Group type: EXPERIMENTAL
Intervention: 566C80 750 mg three times daily for 5 days, then twice daily for 16 days
Number of subjects: 20
Study 2010637 — intervention group
Group type: EXPERIMENTAL
Intervention: 566C80 (various dosages: 100, 250, 750, 1500 mg)
Number of subjects: 20
Study 7035299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g daily for three days)
Number of subjects: 55
Study 7035299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 55
Study 7035299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 55
Study 7035299 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of encephalopathy, serum bilirubin > 340 micromol/l, serum creatinine > 250 micromol/l, histological evidence of cirrhosis
Number of subjects: 55
Study 31954466 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 907
Study 31954466 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 907
Study 30827132 — intervention group
Group type: EXPERIMENTAL
Intervention: BART - LVH
Number of subjects: 4714
Study 30827132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow-Lyon - LVH
Number of subjects: 4714
Study 30827132 — intervention group
Group type: EXPERIMENTAL
Intervention: Peguero-Lo Presti
Number of subjects: 4714
Study 30827132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell voltage product
Number of subjects: 4714
Study 30827132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell voltage
Number of subjects: 4714
Study 30827132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging - LVH
Number of subjects: 4714
Study 30827132 — intervention group
Group type: COMPARATOR
Intervention: Traditional ECG - LVH criteria
Number of subjects: 4714
Study 29415175 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 498
Study 29415175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 27119940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light therapy
Number of subjects: 28
Study 27119940 — intervention group
Group type: COMPARATOR
Intervention: Sham light therapy
Number of subjects: 28
Study 24742364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iodinated activated charcoal (IAC)
Number of subjects: 40
Study 24742364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22728413 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated drink (CAF‐‐5 mg · kg(‐1))
Number of subjects: 24
Study 22728413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 20670325 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-immersion virtual reality (VR) training
Number of subjects: 15
Study 20670325 — intervention group
Group type: COMPARATOR
Intervention: Standardized patient (SP) drill
Number of subjects: 15
Study 17889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based radiology simulator
Number of subjects: 12
Study 17889344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator)
Number of subjects: 12
Study 17889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 12
Study 16238677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 120 IU kg(‐1) s.c. twice daily for 5‐7 days followed by 5,000 or 7,500 IU twice daily for 3 months
Number of subjects: 555
Study 16238677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 555
Study 16238677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 11889300 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioglycolate transport medium
Number of subjects: 30
Study 11889300 — intervention group
Group type: COMPARATOR
Intervention: Saline transport medium
Number of subjects: 30
Study 9440409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week clerkship in physical medicine and rehabilitation
Number of subjects: 0
Study 9440409 — intervention group
Group type: COMPARATOR
Intervention: Pre-clerkship knowledge assessment
Number of subjects: 0
Study 7879323 — intervention group
Group type: EXPERIMENTAL
Intervention: High energetic shock wave treatment (Lithotripter MFL 5000, 2000 impulses per session, 2 sessions, energy 18 kV‐22 kV)
Number of subjects: 20
Study 7879323 — intervention group
Group type: EXPERIMENTAL
Intervention: High energetic shock wave treatment
Number of subjects: 20
Study 2295223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melphalan (0.25 mg/kg) alone
Number of subjects: 10
Study 2295223 — intervention group
Group type: COMPARATOR
Intervention: Oral melphalan (0.25 mg/kg) after interferon (7 x 10(6) IU/m2)
Number of subjects: 10
Study 2295223 — intervention group
Group type: COMPARATOR
Intervention: Interferon administration
Number of subjects: 10
Study 31358085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 50
Study 31358085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28406394 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day)
Number of subjects: 253
Study 28406394 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (0.5 mg/kg/day)
Number of subjects: 253
Study 26656280 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) 3 times a week for 16 weeks
Number of subjects: 24
Study 26656280 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 24
Study 26656280 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 24
Study 25331030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin 0.03 mg/kg intravenous infusion twice daily
Number of subjects: 117
Study 25331030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 25331030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin
Number of subjects: 117
Study 21863263 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (OCT)
Number of subjects: 68
Study 21863263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (LAN)
Number of subjects: 68
Study 19887796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapamycin (4 mg loading dose followed by 2 mg daily for 30 days)
Number of subjects: 108
Study 19887796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 19887796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapamycin
Number of subjects: 108
Study 17394729 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 2641
Study 15680531 — intervention group
Group type: EXPERIMENTAL
Intervention: Two handed chest compression
Number of subjects: 30
Study 15680531 — intervention group
Group type: COMPARATOR
Intervention: One handed chest compression
Number of subjects: 30
Study 15680531 — intervention group
Group type: EXPERIMENTAL
Intervention: Two handed technique
Number of subjects: 30
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbic system perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingulate cortex perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Parahippocampal cortex perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Amygdala/entorhinal cortex perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal area perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior thalamus perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cingulate cortex perfusion in AD patients
Number of subjects: 40
Study 12111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal forebrain, hypothalamus, mamillary bodies, orbitofrontal cortex perfusion in AD patients
Number of subjects: 40
Study 10440971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) for 1 hour per day for 4 weeks
Number of subjects: 15
Study 10440971 — intervention group
Group type: COMPARATOR
Intervention: Control condition with dim light exposure for 4 weeks
Number of subjects: 15
Study 7752281 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg or 40 mg of lovastatin
Number of subjects: 431
Study 7752281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 1982614 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 34
Study 1982614 — intervention group
Group type: COMPARATOR
Intervention: Azatadine 1 mg twice daily
Number of subjects: 34
Study 361143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 241
Study 361143 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 241
Study 31352083 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-producing milk
Number of subjects: 54
Study 31352083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27815351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week from Week 4 to Week 52
Number of subjects: 0
Study 27815351 — intervention group
Group type: COMPARATOR
Intervention: Placebo every other week from Week 4 to Week 52
Number of subjects: 0
Study 25723494 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 22
Study 23802703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test measurement (12 true/false statements)
Number of subjects: 237
Study 23802703 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV leaflet reading
Number of subjects: 237
Study 21923647 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative condition
Number of subjects: 0
Study 21923647 — intervention group
Group type: COMPARATOR
Intervention: Individual condition
Number of subjects: 0
Study 21923647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency words
Number of subjects: 0
Study 21923647 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency words
Number of subjects: 0
Study 21923647 — intervention group
Group type: EXPERIMENTAL
Intervention: Remember (R) responses
Number of subjects: 0
Study 21923647 — intervention group
Group type: EXPERIMENTAL
Intervention: Know (K) responses
Number of subjects: 0
Study 19338141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of lamivudine 40 mg and stavudine 10 mg tablet for oral suspension
Number of subjects: 0
Study 19338141 — intervention group
Group type: COMPARATOR
Intervention: Individual liquid formulations of lamivudine and stavudine
Number of subjects: 0
Study 17768267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 290
Study 17768267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood improvement
Number of subjects: 290
Study 17768267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 17768267 — intervention group
Group type: COMPARATOR
Intervention: Non-recovered post-ACS control group
Number of subjects: 290
Study 15302717 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback and abdominal breathing through pursed lips and prolonged exhalation
Number of subjects: 94
Study 15302717 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback alone
Number of subjects: 94
Study 15302717 — intervention group
Group type: COMPARATOR
Intervention: Placebo EEG biofeedback
Number of subjects: 94
Study 15302717 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 94
Study 12184348 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for depression (8 weeks duration)
Number of subjects: 38
Study 12184348 — intervention group
Group type: COMPARATOR
Intervention: Established treatments for Major Depression
Number of subjects: 38
Study 9041569 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms.kg-1 i.m.
Number of subjects: 45
Study 9041569 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 30 micrograms.kg-1 orally
Number of subjects: 45
Study 9041569 — intervention group
Group type: COMPARATOR
Intervention: No atropine (control group)
Number of subjects: 45
Study 7946257 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 8
Study 7946257 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 8
Study 7946257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7946257 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8
Study 3108921 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 36
Study 3108921 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam
Number of subjects: 36
Study 3108921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29789410 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ATL1103 200 mg twice weekly for 13 weeks
Number of subjects: 26
Study 29789410 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous ATL1103 200 mg once weekly for 13 weeks
Number of subjects: 26
Study 28264717 — intervention group
Group type: EXPERIMENTAL
Intervention: MOBIGAME smartphone-based game application (24 weeks duration)
Number of subjects: 42
Study 28264717 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle counseling (one-time intervention)
Number of subjects: 42
Study 25310336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching program with STJ positioned in pronation
Number of subjects: 22
Study 25310336 — intervention group
Group type: COMPARATOR
Intervention: Gastrocnemius stretching program with STJ positioned in supination
Number of subjects: 22
Study 24968520 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole + FSH
Number of subjects: 55
Study 24968520 — intervention group
Group type: COMPARATOR
Intervention: only FSH
Number of subjects: 55
Study 21173006 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved blood pressure monitoring (near-continuous, noninvasive device)
Number of subjects: 94
Study 21173006 — intervention group
Group type: COMPARATOR
Intervention: Intermittent blood pressure monitoring (oscillometric device)
Number of subjects: 94
Study 18355408 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation PermaNet
Number of subjects: 0
Study 18355408 — intervention group
Group type: EXPERIMENTAL
Intervention: First generation PermaNet
Number of subjects: 0
Study 18355408 — intervention group
Group type: COMPARATOR
Intervention: Conventionally treated nets
Number of subjects: 0
Study 16971717 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 619
Study 16971717 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stent
Number of subjects: 619
Study 15319242 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 40 mg/m2 weekly for 6 consecutive weeks followed by 2 weeks without treatment (n = 41)
Number of subjects: 83
Study 15319242 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 100 mg/m2 on day 1 every 3 weeks (n = 42)
Number of subjects: 83
Study 11545756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site RA pacing with overdrive algorithm
Number of subjects: 22
Study 11545756 — intervention group
Group type: COMPARATOR
Intervention: High right atrial pacing at 30 beats/min (Off)
Number of subjects: 22
Study 15102427 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 150
Study 15102427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous infiltration with 2% lidocaine
Number of subjects: 150
Study 15102427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 150
Study 15102427 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 150
Study 15102427 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 150
Study 8218959 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide formulation 1 (100 mg)
Number of subjects: 8
Study 8218959 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide formulation 2 (100 mg)
Number of subjects: 8
Study 2446757 — intervention group
Group type: EXPERIMENTAL
Intervention: Imunovir
Number of subjects: 106
Study 2446757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 28158421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BVS)
Number of subjects: 110
Study 28158421 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium metallic stent (CoCr-EES)
Number of subjects: 110
Study 27245914 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula alone
Number of subjects: 82
Study 27245914 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 82
Study 27245914 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation plus interspaced high-flow nasal cannula
Number of subjects: 82
Study 25012121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy, treatment three times a week for 5 weeks.
Number of subjects: 100
Study 25012121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy, treatment three times a week for 5 weeks.
Number of subjects: 100
Study 22064876 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-office collaborative care (DOCC)
Number of subjects: 78
Study 22064876 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 78
Study 18274949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 50)
Number of subjects: 116
Study 18274949 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 66)
Number of subjects: 116
Study 15868003 — intervention group
Group type: COMPARATOR
Intervention: Pedicled group (PG)
Number of subjects: 50
Study 15868003 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized group (SG)
Number of subjects: 50
Study 15868003 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SG to PG after topical vasodilator application
Number of subjects: 50
Study 14506498 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 40
Study 14506498 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 40
Study 10584722 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA), n=129
Number of subjects: 263
Study 10584722 — intervention group
Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium (TCRE), n=134
Number of subjects: 263
Study 10584722 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 263
Study 10584722 — intervention group
Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium (TCRE)
Number of subjects: 263
Study 8543518 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to parental conflict
Number of subjects: 140
Study 8543518 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to parental psychopathology
Number of subjects: 140
Study 8543518 — intervention group
Group type: COMPARATOR
Intervention: Normal control probands
Number of subjects: 140
Study 2509916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of recombinant interferon alfa three times weekly for 24 weeks
Number of subjects: 166
Study 2509916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of recombinant interferon alfa three times weekly for 24 weeks
Number of subjects: 166
Study 2509916 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 166
Study 2509916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon
Number of subjects: 166
Study 2509916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of interferon
Number of subjects: 166
Study 31930627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfaction with life
Number of subjects: 323
Study 31930627 — intervention group
Group type: EXPERIMENTAL
Intervention: Living without a spouse
Number of subjects: 323
Study 31930627 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of leisure time activity
Number of subjects: 323
Study 31567876 — intervention group
Group type: EXPERIMENTAL
Intervention: HALC with high MIAT levels
Number of subjects: 320
Study 31567876 — intervention group
Group type: EXPERIMENTAL
Intervention: HALC with MIAT level <10.9 in CC tissue or <8.7 in serum
Number of subjects: 320
Study 31567876 — intervention group
Group type: COMPARATOR
Intervention: LAC
Number of subjects: 320
Study 28800501 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback (BF) training
Number of subjects: 18
Study 28800501 — intervention group
Group type: COMPARATOR
Intervention: Visual biofeedback (BF) training
Number of subjects: 18
Study 26329913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a rate of 0.4 μg kg(‐1) h(‐1)
Number of subjects: 90
Study 26329913 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a rate of 0.05 μg kg(‐1) min(‐1)
Number of subjects: 90
Study 26329913 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 90
Study 26329913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 90
Study 26329913 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 90
Study 23497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI) maneuver (25 cmH2O for 15 seconds) followed by nasal continuous positive airway pressure (NCPAP)
Number of subjects: 276
Study 23497495 — intervention group
Group type: COMPARATOR
Intervention: NCPAP alone
Number of subjects: 276
Study 23497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI) maneuver
Number of subjects: 276
Study 21877678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical epithelial debridement
Number of subjects: 33